Research Analysts’ Recent Ratings Updates for Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (NASDAQ: IONS) recently received a number of ratings updates from brokerages and research firms:

• 11/12/2024 – Ionis Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/7/2024 – Ionis Pharmaceuticals had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an “overweight” rating on the stock.
• 11/7/2024 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
• 11/4/2024 – Ionis Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/25/2024 – Ionis Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/9/2024 – Ionis Pharmaceuticals had its price target lowered by analysts at Guggenheim from $70.00 to $65.00. They now have a “buy” rating on the stock.
• 9/26/2024 – Ionis Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $70.00 price target on the stock.

Ionis Pharmaceuticals Stock Up 0.0 %

Shares of NASDAQ:IONS opened at $37.78 on Thursday. The company has a market capitalization of $5.97 billion, a price-to-earnings ratio of -15.48 and a beta of 0.39. The company has a 50 day moving average of $40.09 and a two-hundred day moving average of $42.84. Ionis Pharmaceuticals, Inc. has a 52-week low of $35.95 and a 52-week high of $54.44. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86.

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Great Point Partners LLC acquired a new position in shares of Ionis Pharmaceuticals in the 2nd quarter worth approximately $15,728,000. International Assets Investment Management LLC grew its holdings in shares of Ionis Pharmaceuticals by 3,287.0% during the third quarter. International Assets Investment Management LLC now owns 328,772 shares of the company’s stock valued at $13,171,000 after buying an additional 319,065 shares in the last quarter. Logos Global Management LP acquired a new position in Ionis Pharmaceuticals during the second quarter valued at $14,298,000. Zimmer Partners LP purchased a new stake in Ionis Pharmaceuticals in the 1st quarter worth about $11,718,000. Finally, Marshall Wace LLP grew its stake in Ionis Pharmaceuticals by 1,021.5% during the 2nd quarter. Marshall Wace LLP now owns 173,199 shares of the company’s stock valued at $8,255,000 after acquiring an additional 157,756 shares in the last quarter. 93.86% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.